AC
ALNY icon

Apogem Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Apogem Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,669
Closed -$273K – 159
2022
Q1 		$273K Sell
1,669
-729
-30% -$111K 0.19% 135
2021
Q4 		$407K Buy
+2,398
New +$446K 0.27% 114

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Apogem Capital's ALNY Position: Q2 2022 in Review

Apogem Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2022, closing a stake of 1,669 shares — an estimated $273K sold.

Apogem Capital first reported a position in ALNY in Q4 2021 and held it in 2 quarters. The position peaked at $407K in Q4 2021. 423 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

  • Apogem Capital reported no remaining Alnylam Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Apogem Capital sold 1,669 Alnylam Pharmaceuticals shares in Q2 2022, an estimated $273K.
  • Apogem Capital first reported a position in Alnylam Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Apogem Capital's Alnylam Pharmaceuticals position peaked at $407K in Q4 2021.
  • 423 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on Apogem Capital's 13F filing for Q2 2022, filed 15 Aug 2022.